3Bulman N, Levy Y, Leiba R,et al. Increased C-reactive protein levels in the polycystic orary syndrome:a marker of cardio vascular disease [ J]. J Clin Endocrinol Metab,2004,89:2160.
6Tanaka M. Pharmacological and clinical profile of the free radical scavenger edaravonger as a neuroprotective agent [ J ]. Nippon Yakurigku Zasshi ,2002,119 ( 5 ) :301-308.
7Ikeda T, Xi YX, Kanelo M, et al. Effect of the free radical scavenger, 3-methyl-1 -phenyl-2-pyrazolin-5-one( MCI-186), on hypoxia-ischemia-induced brain injury in neonatal rats [ J ]. Neuroscilett, 2002,329 ( 1 ) :33-36.
8Satoh K, Ikeda Y, Shioda S, et al. Edaravone scavenges nitric oxide [J]. Redox Rep,2002,7(4) :219-222.
二级参考文献24
1Libby P, Ridker PM, Maseri A. Inflammation and atherosclercsis. Circulation, 2002, 105: 1135-1143.
2Kharbanda RK, Walton B, Allen M, et al. Prevention of inflammation-induced endothelial dysfunction: a novel vasculo-protective action of aspirin.Circulation, 2002, 105: 2600-2604.
3Nakajima T, Schuhe S, Warrington KJ, et al. T-cell-mediated lysis of endothelial cells in acute coronary syndromes. Circulation, 2002, 105: 570-575.
4Verma S, Li SH, Badiwala MV, et al. Endothelin antagonism and interleuldn-6 inhibition attenuate the proatherogenic effects of C-reactlve protein.Circulation. 2002, 105: 1890-1896.
5Sampietro T, Bigazzi F, Dal Pino B, et al. Increased plasma C-reactive protein in familial hypoalphalipoproteinemia: a proinflammation condition? Circulation, 2002, 105: 11-14.
6Rajamannan NM, Subramanian M, Springett M, et al. Atorvastatin inhibits hypercholesterolemia-induced cellular proliferation and bone matrix production in the rabbit aortic valve. Circulation, 2002, 105: 2660-2665.
7Hayaishi-Okano R, Yamaski Y, Katakami N, et al. Elevated C-reactive protein associates witheady-stage carotid atherosclerosis in young subjects with type 1 diabetes. Diabetes Care, 2002, 25: 1432-1438.
8Prasad A, Zhu J, Halcox JP, et al. Predisposition to atheroscleroeis by infections: role of endothelial dysfunction. Circulation, 2002, 106: 184-190.
9Parchure N, Zouridakis EG, Kaski JC. Effect of azithromycin treatment on endothelial function in patients with coronary artery disease and evidence of Chlamydia pneumoniae infection. Circulation, 2002, 105: 1298-1303.
10Wiesli P, Czerwenka W, Meniconi A, et al. Roxithromycin treatment prevents progression of peripheral arterial occlusive disease in Chlamydia pneumoniae seropositive men: a randomized, double-blind, placebo-controlled trial. Circulation, 2002, 105: 2646-2652.
